Related coverage linked through entity extraction aliases.
May 07, 2026
Merck's Enflonsia (clesrovimab) receives EU approval for RSV prevention in infants. Separately, researchers identify a monoclonal antibody cocktail from pediatricians' immune cells that shows potent protection against RSV and hMPV in animal studies.
Apr 21, 2026
Regeneron said the Phase 3 NIMBLE trial of cemdisiran in generalized myasthenia gravis met primary and key secondary endpoints at week 24. The company said a U.S. regulatory application has been submitted and EU filings are planned for 2026.
Apr 14, 2026
Breath Diagnostics said the FDA granted Breakthrough Device Designation to its OneBreath platform for pre-operative assessment of postoperative pneumonia risk in adults undergoing elective cardiac surgery. The single-breath test analyzes exhaled volatile organic compounds using LC-MS and is intended for use with clinical evaluation and standard risk assessment tools.
Mar 25, 2026
Research shows chloramine disinfection successfully stopped a Legionnaires' disease outbreak in Minnesota, while clinical data reveals Legionella pneumonia has 11.9% 30-day mortality and disproportionately affects immunocompromised patients. The studies highlight both prevention strategies and diagnostic challenges.
Mar 13, 2026
The World Health Organization published blueprints for urgently needed antibiotics targeting drug-resistant infections, while CARB-X awarded $1.2 million for novel antibiotic research and the FDA issued guidance on antibiotic duration limits in livestock.
Mar 06, 2026
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
Mar 06, 2026
Children with obstructive sleep apnea face nearly twice the risk of contracting influenza or COVID-19 compared to controls, with increased vulnerability persisting even after adenotonsillectomy, according to a five-year study of over 1 million children.
Mar 06, 2026
The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.
Feb 21, 2026
A measles exposure occurred on February 18 at Nemours Children's Hospital emergency department in Delaware. State health officials are conducting contact tracing and urging unvaccinated exposed individuals to receive MMR vaccine within 72 hours.
Feb 11, 2026
Obesity contributes to about 1 in every 4 infectious disease deaths in the United States and 1 in 10 globally, according to a major study. People with obesity face 70% higher risk of hospitalization or death from infections, with risk tripling at severe obesity levels.
Oct 01, 2025
The FDA approved Zycubo (copper histidinate) on January 13, 2026, as the first treatment for Menkes disease in pediatric patients, following resolution of manufacturing compliance concerns that led to an initial rejection in September 2025.
Feb 12, 2026
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
Feb 11, 2026
Measles cases are rising across multiple states, with over 40 cases at a Florida college and 18 cases in North Carolina since December. Federal health officials are urging vaccination as the U.S. recorded 2,280 cases in 2025.
